Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Step Therapy Coverage | …
    Ask Trek AI about this page
    CurrentIndependent HealthPolicy N/A

    Step Therapy Criteria — Medicare Advantage Standard Part D Formulary

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy requirements for specific drugs on Independent Health's 2026 Medicare Advantage Standard Part D formulary; affects providers prescribing and pharmacists processing Part D claims for members covered under this formulary.

    Policy Summary
    PayerIndependent Health
    PolicyStep Therapy Criteria — Medicare Advantage Standard Part D Formulary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionProviders must document prior use and intolerance or inadequate response to required first-line agents when requesting coverage for non-preferred drugs under step therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Medicare Advantage Part DFormulary

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~14
    Listed entries
    ManyProducts with step=1

    Product-specific Step Therapy Criteria

    Aliskiren (300 mg) step requirement

    aliskiren fumarate tablet 300 mg requires prior use of an ARB

    aliskiren 300 mg step: Coverage requires trial of an angiotensin-II receptor blocker (ARB) first.

    Supports aliskiren fumarate 300 mg oral

    Aripiprazole sequencing

    Aripiprazole formulations sequencing

    Aripiprazole ODT: Aripiprazole orally-disintegrating tablet (ODT) requires prior use of aripiprazole oral solution.

    Applies to ODT presentations

    Aripiprazole film: Aripiprazole oral films require prior use of aripiprazole ODT.

    Applies to OPIPZA film products

    EUCRISA

    EUCRISA step requirement

    EUCRISA ointment 2%: Requires use of either a topical corticosteroid or topical calcineurin inhibitor first.

    Topical nonsteroidal alternatives required before EUCRISA

    Febuxostat

    Febuxostat step requirement

    Febuxostat 40 mg and 80 mg: Requires the use of allopurinol first.

    Applies to both 40 mg and 80 mg strengths

    SYMPAZAN

    SYMPAZAN films sequencing

    SYMPAZAN films require prior use of clobazam oral suspension.

    Applies to 5 mg, 10 mg, 20 mg film presentations

    TRELSTAR MixJect

    TRELSTAR MixJect sequencing

    TRELSTAR MixJect (various doses): Requires the use of Lupron Depot first.

    Applies to listed reconstituted intramuscular presentations

    VERSACLOZ and doxercalciferol

    Clozapine and doxercalciferol sequencing

    VERSACLOZ suspension 50 mg/mL: Requires the use of clozapine orally-disintegrating tablet first.

    Applies to clozapine suspension

    Doxercalciferol capsules: Doxercalciferol 2.5 mcg (and indexed presentations) require prior use of calcitriol first.

    Applies to 0.5, 1, and 2.5 mcg presentations as indexed

    Required First-line Agents

    Initial therapy requirements

    Required first-line agents for select products

    aliskiren 300 mg: Trial of an angiotensin-II receptor blocker (ARB) required before coverage.

    From Details chunk

    Aripiprazole initial therapy

    Aripiprazole initial therapy

    Aripiprazole ODT and films: Aripiprazole ODT requires prior trial of oral solution; aripiprazole films require prior trial of ODT.

    From Details chunk

    Step Requirements and Required Prior Agents

    DrugRequired first-step therapyCoverage
    EUCRISA ointment 2% (external)Topical corticosteroid or topical calcineurin inhibitorRequires trial of a topical corticosteroid or topical calcineurin inhibitor before coverage of EUCRISA (step 1)
    DrugRequired first-step therapyCoverage
    Febuxostat tablet 40 mgAllopurinolRequires trial of allopurinol before coverage of febuxostat 40 mg (step 1)
    Febuxostat tablet 80 mgAllopurinolRequires trial of allopurinol before coverage of febuxostat 80 mg (step 1)
    DrugRequired first-step therapyCoverage
    SYMPAZAN film (5 mg, 10 mg, 20 mg)Clobazam oral suspensionRequires trial of clobazam oral suspension before coverage of SYMPAZAN films (step 1)
    DrugRequired first-step therapyCoverage
    TRELSTAR MixJect suspension (3.75 mg, 11.25 mg, 22.5 mg IM recon. presentations)Lupron DepotRequires trial of Lupron Depot before coverage of TRELSTAR MixJect suspensions (step 1)
    DrugRequired first-step therapyCoverage
    VERSACLOZ suspension 50 mg/mL oralClozapine orally-disintegrating tablet (ODT)Requires trial of clozapine ODT before coverage of VERSACLOZ suspension (step 1)
    DrugRequired first-step therapyCoverage
    Doxercalciferol capsule 2.5 mcg oralCalcitriolRequires trial of calcitriol before coverage of doxercalciferol 2.5 mcg capsule (step 1)
    DrugRequired first-step therapyCoverage
    Aliskiren fumarate tablet 300 mg oralAngiotensin-II receptor blocker (ARB)Requires trial of an ARB before coverage of aliskiren fumarate 300 mg (step 1)

    What Providers and Pharmacists Must Do

    Prior Authorization

    Step therapy may require prior authorization for Part D formulary

    Step therapy protocols apply to the Medicare Advantage Part D formulary and may require prior authorization when the member has not met step requirements; this list pertains to Independent Health's 2026 Medicare Advantage Standard Part D Formulary and contains the associated Step Therapy protocols.

    • Contact Medicare Member Services with questions: 1-800-665-1502 (TTY 711).
    Note

    Overview — product-level required first-line therapies

    Specific product-level first-line therapies are required before coverage of listed non-preferred products; see the per-product entries in this policy (coverage.module and drug_policy) for the required first-step agents (for example: ARB before aliskiren 300 mg; topical corticosteroid or topical calcineurin inhibitor before EUCRISA; allopurinol before febuxostat; clobazam oral suspension before SYMPAZAN films; Lupron Depot before TRELSTAR MixJect; clozapine ODT before VERSACLOZ; calcitriol before doxercalciferol).

    Policy Summary
    PayerIndependent Health
    PolicyStep Therapy Criteria — Medicare Advantage Standard Part D Formulary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionProviders must document prior use and intolerance or inadequate response to required first-line agents when requesting coverage for non-preferred drugs under step therapy.
    SourceLink
    On This Page
    Product-specific Step Therapy CriteriaRequired First-line AgentsStep Requirements and Required Prior AgentsWhat Providers and Pharmacists Must Do
    Documentation Required

    Document prior use and inadequate response or intolerance

    When requesting coverage for a non-preferred product under step therapy, providers should document prior use and either inadequate response or intolerance to the required first-line agent(s).

    • Documentation should show trial of the required first-step agent(s) and reason for failure (intolerance or inadequate response).
    Denial Risk

    Noncompliance with step therapy can lead to claim denial

    Claims may be denied or not covered if step therapy requirements are not met; prescribers must ensure required first-step agents were tried and documented before submitting claims for non-preferred products.

    • Failure to meet step requirements (e.g., not trying the specified first-line agent) can result in denial of coverage for the requested drug.